Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer ...
The designation gives HeartBeam prioritized FDA interaction as it prepares a pivotal study of its 3D ECG technology for assessing suspected heart attacks outside traditional medical settings. Key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results